Linda Wenger
[email protected]
(973) 449-3214
WASHINGTON, DC (August 27, 2020) — LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced today the launch of new longitudinal study in collaboration with the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) titled Understanding the lung cancer Patient ExperiEnce in the Real-world setting (Project PEER). The overarching goal of Project PEER is to understand the lung cancer patient experience, irrespective of diagnosis (stage/histology), outside of the clinical trial setting.
The Project PEER collaboration seeks to systematically understand how patients with lung cancer feel and function and whether this experience is affected by their specific diagnosis and treatment. The real-world data from Project PEER will be used to explore patterns in patient experiences and compare those patterns to what is seen in clinical trial data within the same patient population.
LUNGevity and the FDA have signed a multi-year Research Collaboration Agreement to work together on Project PEER. FDA OCE investigators will have the opportunity through the collaboration to understand different aspects of patient experience (e.g., impact of a diagnosis on physical role-functioning, emotional well-being) in a real-world setting using standardized patient-reported outcome (PRO) instruments commonly used in cancer clinical trials. De-identified data collected through Project PEER will be available to FDA-CDER investigators as well as third-party investigators free of charge. The data collected is not meant for registrational purposes and is meant to be exploratory and hypothesis-generating only.
“In the last few years, science has progressed at an unprecedented rate as new categories of therapies have become available and the application of existing therapies has expanded,” says Dr. Upal Basu Roy, PhD, MPH, Vice President of Research at LUNGevity and project lead of Project PEER at LUNGevity. “However, reasons for treatment discontinuation (adverse events, progression, mechanisms of resistance, etc.) are not well documented beyond a clinical trial context. Similarly, how patients experience their disease in terms of symptoms, impacts, outcomes, and quality of life throughout their disease progression is unclear. We are excited to launch this study to better understand these issues and, ultimately, help provide the best care possible to the lung cancer community.”
The project will be using the EmpiraMed™ PRO Portal™ Software Platform that deploys 100% site-less virtual studies to better evaluate patient experience in the real world. The EmpiraMed PRO Portal will be used to allow study participants to participate in Project PEER more easily while compensating them for their data and time in an engaging manner.
“LUNGevity is proud to collaborate with the FDA to better understand the lung cancer patient experience,” says Andrea Ferris, President and CEO of LUNGevity. “Project PEER provides the Agency real-world data about how our patient population, particularly those underrepresented in clinical trials, respond to therapies. Our collaboration with the FDA has the potential to make an impact on the future of treatment for lung cancer, resulting in better outcomes for patients.”
“Characterizing how patients with lung cancer experience treatment in the real-world setting is an important opportunity to improve our understanding of cancer therapy,” said Paul Kluetz, MD, Deputy Director of the FDA’s Oncology Center of Excellence. “We are pleased to collaborate with LUNGevity to explore alternative data sources and increase our understanding of the patient experience.”
You can find more information on Project PEER at the study website: https://www.studylc2.empiramed.org/pub/study/lc2
Project PEER is an international study and open to any adult participant with lung cancer or caregiver who is able to read and respond to questions in English. There is no limit on the number of participants or countries included in Project PEER. LUNGevity hopes to enroll around 1,200 patients and 300 caregivers.
About LUNGevity Foundation
LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivors—and those who help them live better and longer lives.
Comprehensive resources include a medically vetted and patient-centric website, a toll-free HELPLine for support, the International Lung Cancer Survivorship Conference, and an easy-to-use Clinical Trial Finder, among other tools. All of these programs are to achieve our vision—a world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization.
Please visit www.LUNGevity.org to learn more.
About Lung Cancer in the US
- About 1 in 16 Americans will be diagnosed with lung cancer in their lifetime.
- More than 228,000 people in the US will be diagnosed with lung cancer this year.
- About 60%-65% of all new lung cancer diagnoses are among people who have never smoked or are former smokers.
- Lung cancer takes more lives than the next three leading cancers (colorectal, breast, and prostate) combined.
- Only 19% of all people diagnosed with lung cancer will survive 5 years or more, BUT if it is caught before it spreads, the chance of 5-year survival improves dramatically.